U.S. markets closed

Pacific Biosciences Introduces Enhancements to Sequel System

Zacks Equity Research
The latest enhancements in Pacific Biosciences??? (PACB) Sequel System represent strong improvement in terms of read length, throughput and accuracy in DNA sequencing.

Pacific Biosciences of California, Inc. PACB recently introduced new enhancements to its flagship DNA-sequencing platform — the Sequel System. The features include a new version (6.0) of its software, new consumable reagents (3.0) and the latest SMRT Cell (1M v3).

Per management, the enhancements indicate a strong improvement in terms of read length, throughput and accuracy during DNA sequencing. These will improve the performance and affordability of Single Molecule, Real-Time (SMRT) sequencing by providing individual long reads with more than 99% accuracy.

Pacific Biosciences: a Leading Name in Genomics

The Sequel system has been fortifying Pacific Biosciences’international footprint in the genomics market.

The company’s SMRT sequencing technology helps scientists observe the DNA synthesis in real time by harnessing the natural process of replication initiated by the enzyme DNA polymerase. The system is a nucleic acid sequencing platform based on SMRT technology.

Favorable Trends Drive Genomics Markets

Genomics has received a warm response from the MedTech investment space. Per Markets and Markets, the global Genomics market, which was worth $13.45 billion in 2016, is expected to reach $23.88 billion by 2022 at a CAGR of 10.2%.

The global Genomics markets have benefited from a streak of solid developments in sequencing, microarray, Polymerase Chain Reaction (PCR), Nucleic acid extraction and Purification techniques.

Further, the implications of Artificial Intelligence (AI), cloud-based technologies and R&D focus have provided the companies with significant exposure to Genomics and a competitive edge in the MedTech space of late.

There are other companies poised to gain from the rising influence of Genomics on MedTech. Illumina Inc’s ILMN portfolio of sequencing platforms comprises systems that are designed to meet the workflow, output and accuracy demands of a full range of sequencing applications.

Thermo Fisher Scientific, Inc TMO offers a comprehensive portfolio of genotyping solutions for SNP, indel and CNV analysis.

QIAGEN N.V. QGEN currently offers one of the broadest portfolios of molecular technologies for human healthcare.

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
Pacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report
Illumina, Inc. (ILMN) : Free Stock Analysis Report
QIAGEN N.V. (QGEN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research